FDA Grants Accelerated Approval to Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer

FDA granted accelerated approval to dostarlimab for adults with previously untreated stage II/III MSI-H/dMMR locally advanced rectal cancer based on the AZUR-1 trial results, demonstrating significant clinical complete response rates and enabling many patients to avoid surgery and chemoradiation.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.